LDLR-Mediated Neuroinflammation Modulation Strategy

The LDLR-Mediated Neuroinflammation Modulation Strategy proposes that direct pharmacological enhancement of LDLR expression and activity within brain microglia and astrocytes can ameliorate neuroinflammatory processes through improved clearance of oxidized lipoproteins and inflammatory lipid species. Unlike traditional approaches targeting peripheral cholesterol metabolism, this strategy focuses on the brain-intrinsic role of LDLR in maintaining CNS lipid homeostasis and inflammatory resolution. The mechanism centers on LDLR’s capacity to internalize not only LDL particles but also modified lipoproteins, lipopolysaccharide complexes, and other inflammatory cargo that accumulate during neuroinflammation. In activated microglia, upregulated LDLR expression correlates with enhanced phagocytic clearance and transition from pro-inflammatory M1 to anti-inflammatory M2 phenotypes. The strategy employs small-molecule LDLR agonists or liver X receptor (LXR) modulators that specifically cross the blood-brain barrier to enhance LDLR transcription via sterol regulatory element-binding proteins (SREBPs). This approach targets the APOE-LDLR axis within the CNS, where APOE4 variants associated with neurodegeneration exhibit reduced LDLR binding affinity, leading to impaired lipid clearance and sustained inflammatory activation. By pharmacologically compensating for this deficiency through LDLR upregulation, the strategy aims to restore efficient clearance of neurotoxic lipid species, reduce microglial activation, and promote neuroprotective signaling cascades. Clinical applications include Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, where chronic neuroinflammation and lipid dysmetabolism contribute to progressive neurodegeneration. The intervention specifically targets brain-resident cells rather than peripheral tissues, offering a CNS-selective therapeutic approach.